Allergy and Immunology; Antibodies
- Antibody Research
Molecular, immunological and structural characterization of allergen-specific antibodies and nanobodies to answer fundamental questions regarding the interaction allergen/IgE antibodies as well as to develop tools for diagnosis, prevention and treatment of allergy.
Techniques, methods & infrastructure
Our expertise includes a broad spectrum of state-of-the-art-methodologies in molecular and cellular biology and immunology, e.g. generation of antibody/nanobody libraries, phage display technology, isolation and characterization of monoclonal antibodies/nanobodies, cell culture, mediator release experiments, DNA cloning, ELISA, immunoblotting, Biacore, mouse models.
- Allergen-specific approaches targeting the nasal mucosa for treatment and prevention of allergy (2020)
Source of Funding: Medical University of Vienna, Danube Allergy Research Cluster ( Danube ARC)
- ICAM1 and allergen-specific nanobodies for allergy treatment (2019)
Source of Funding: FWF (Austrian Science Fund), Internationale Programme
- Weichwald, C. et al. (2023) ‘Antibody Conjugates Bispecific for Pollen Allergens and ICAM-1 with Potential to Prevent Epithelial Allergen Transmigration and Rhinovirus Infection’, International Journal of Molecular Sciences, 24(3), p. 2725. Available at: http://dx.doi.org/10.3390/ijms24032725.
- Zettl, I. et al. (2022) ‘Generation of high affinity ICAM-1-specific nanobodies and evaluation of their suitability for allergy treatment’, Frontiers in Immunology, 13. Available at: http://dx.doi.org/10.3389/fimmu.2022.1022418.
- Zettl, I. et al. (2021) ‘Isolation of nanobodies with potential to reduce patients’ IgE binding to Bet v 1’, Allergy, 77(6), pp. 1751–1760. Available at: http://dx.doi.org/10.1111/all.15191.
- Flicker, S., Zettl, I. and Tillib, S.V. (2020) ‘Nanobodies—Useful Tools for Allergy Treatment?’, Frontiers in Immunology, 11. Available at: http://dx.doi.org/10.3389/fimmu.2020.576255.
- Gadermaier, E. et al. (2018) ‘Isolation of a high-affinity Bet v 1-specific IgG-derived ScFv from a subject vaccinated with hypoallergenic Bet v 1 fragments’, Allergy, 73(7), pp. 1425–1435. Available at: http://dx.doi.org/10.1111/all.13394.